Unique administration of drugs with large patient benefits

Karessa is a Swedish pharmaceutical company that aims to revolutionise the market for medicinal products through innovation and a patented drug delivery platform..

Our medicinal products will not be taken in tablet form, but will instead be delivered directly into the bloodstream via a film that is applied discreetly to the oral mucosa. The main advantages for the patient include a faster and more reliable effect compared with today's preparations.

Our business model is based on combining proven, effective and approved substances with our own patented drug delivery platform. Through this combination, we are  generating significant benefits, both for the patient and for Karessa itself. For Karessa as a company, the combination means a shorter time to market, lower development costs and reduced risk compared with traditional drug development.

Erectile dysfunction

Karessa Pharma - Småbolagsdagen Stockholm 3 juni 2019
Presentation by Stefan Arver

The plattform

Plattform presentation

Latest presentation

Senaste presentation
View the latest presentation


Press releases

  • 11/5/2019

    Statement by the Board of Directors of Karessa Pharma in relation to the Merger with Klaria Pharma

    The Board of Directors of Karessa Pharma unanimously recommends that the shareholders of Karessa Pharma vote in favour of the Merger. [1]

  • 11/5/2019

    Klaria Pharma Holding and Karessa Pharma Holding merge to create a focused drug development company with a strong pipeline and a wholly-owned drug-delivery technology platform

    Important Information In the information below, “this press release” refers to this document, its content or part thereof, oral presentations, question papers and written or oral material discussed or distributed in connection therewith. This press release is not a notice to attend an extraordinary general meeting or a merger document. This press release is also not an offer to sell, or a solicitation or invitation to submit an offer to buy, acquire or subscribe for, securities, or an incentive to make any investment, and there will be no sale of securities in jurisdictions where such an offer, request or sale would be prohibited without registration or qualification under such jurisdiction's securities law. Decisions regarding the proposed legal merger between Klaria Pharma Holding AB (publ) ("Klaria") and Karessa Pharma Holding AB (publ) ("Karessa") (the "Merger") shall be made solely on the basis of information stated in the actual notices to attend Klaria’s and Karessa's extraordinary general meetings, as applicable, and the Merger Document relating to the Merger, and to independent analyses of the information therein. You should read the Merger Document, which will be available before the extraordinary general meetings which will decide on the issues set forth herein, to obtain more complete information on the Merger. You should also do an independent analysis of the information contained therein and the merger document before making an investment decision. This press release contains forward-looking information. Forward-looking information is inherently associated with known and unknown risks, uncertainties, assumptions and other factors, as it relates to circumstances and depends on circumstances that occur in the future, whether within or outside the respective companies or New Klaria Pharma's control. Such factors may cause actual results, performance and actual development to deviate significantly from what is expressed or implied in the forward-looking information. Although each company's management believes that their expectations stated in the forward-looking information are reasonable based on such information that is available to them, no guarantee is given that such forward-looking information will prove to be accurate. Undue weight should not be given to forward-looking information. The forward-looking information applies only to the day of this press release and neither Klaria nor Karessa undertake any obligation to update the forward-looking information beyond what is required pursuant to applicable law. Klaria's and Karessa's past performance does not guarantee, and does not represent, the future performance of New Klaria Pharma. Furthermore, Klaria, Karessa and their respective subsidiaries, senior executives, employees and agents undertake no obligation to review, update or confirm expectations or estimates, or revise forward-looking information to reflect events that occur, or circumstances that arise, in relation to the content of the press release. Furthermore, it is not certain that the Merger will be carried out in the manner and within the time frame described in this press release or at all.



Merger with Klaria Pharma Holding

The board of directors of Karessa and Klaria agreed November 5, 2019, on a combination of Klaria and Karessa through a statutory merger. The merger requires support from extra general meetings in both companies.

New directors of the board

Neal Meacham and Kristina Lidén Mascher were elected to the board of Karessa Pharma Holding AB October 22, 2019. 

New Chairman of the Board

Fredrik Hübinette was elected August 22, 2019, as new Chairman of the Board of Karessa. Fredrik, who has a long background in the industry, is behind the invention and the patent on which Karessa's various projects are based.

Karessa meets with investors and partners

Karessa presented the company and its business model and the latest developments at Småbolagsdagen on June 3, organized by Aktiespararna. The meeting was well attended and gave rise to positive discussions. The company was also represented at the Biotech Hanse Forum on June 13 with a presentation.

Karessa will attend the big meeting NLS days in Malmö September 10-12. We will present and discuss the company's projects with prospective international business partners.

Annual general meeting 2019, Karessa

The annual general meeting was held April 25, 2019. Ulf Lindberg, Stefan Arver and Scott Boyer was reelected as board members. Please refer to "Investerare" in Swedish part of web page for more information of decisions taken.

Karessa at BIO-Europe Spring

Karessa participated at the congress in Wienna in March 2019 where biotech companies gathered for individual meetings on opportunities for future collaborations. We presented Karessa and its unique drug delivery technology and research. 1 500 companies and 15 000 delegates participated.

Exciting development of the patented drug delivery platform

Karessa is developing pharmaceuticals based on the unique patented alginate drug delivery technique, where the pharmaceutical is placed in the buccal cavity for direct absorption into the bloodstream. This is also used by the Swedish research company Klaria, which on January 22, 2019, signed an agreement with Purdue Pharma regarding development of Adrenalin for the treatment of acute allergic conditions. The agreement is worth close to 500 million SEK and is the second product in the cooperation. We are seeing an increasing interest in our technology with a quick, direct and effective delivery of the pharmaceutical from the buccal cavity into the bloodstream.

Karessa at NLS days

NLS days were held on September 10-12, 2018, in Stockholm. The meeting gathered about 800 companies and organizations in life science, with 1,200 participants. Karessa participated, among other things with a presentation of the company's business concept and projects within erectile dysfunction facing potential stakeholders and partners.

High frequency of sexual problems associated with prostate cancer

In a new published Scandinavian study on treated prostate cancer patients, patients who were sexually active received major problems with sex life afterwards. Erectile dysfunction and accompanying problems were measured at 72–92% among patients from Scandinavia, and were several times more common than untreated patients. The study highlights the importance of clinical need to care for these patients and help them to improve sexual health and quality of life. 

Karessa's work is mentioned

New article about Karessa's unique platform and development work with drugs to treat erectile dysfunction.

Read the article (in Swedish) ”Utvecklar läkemedel mot impotens” 
(December 2017)

undefined40 per cent of all 40-year-old men are affected

40 per cent of all 40-year-old men suffer from erectile dysfunction, i.e. the inability to achieve and maintain an erection sufficient to enable successful intercourse. The reasons may be physical, mental, or a combination of both. The biggest underlying factors include age, other medications and lifestyle.

Read more about the market for medicinal products treating erectile dysfunction here.